bioRxiv · 10.64898/2026.04.23.719229
TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia
Abstract
DNA methylation dynamics shape hematopoietic differentiation and leukemogenesis; yet how the dioxygenase TET2--frequently mutated in myeloid malignancies--directs lineage-specific regulatory programs remains unclear. Here, we integrated DNA methylation, chromatin accessibility, 3D genome architecture, transcriptional profiling, and TET2 chromatin occupancy to define TET2-dependent control of human myeloid commitment. We found that TET2-bound regulatory regions gain short- and long-range chromatin interactions and that a distinct subset of distal, enhancer-enriched sites undergoes TET2-driven demethylation and activation. Among these, we identified an AGO2 myeloid-specific intragenic enhancer that is frequently hypermethylated in TET2-mutant AML patients. AGO2 expression stratifies patient survival, and AGO2 depletion abrogates leukemic engraftment in vivo. These findings uncover a TET2-AGO2 regulatory axis that integrates epigenetic remodeling, 3D genome reorganization, and leukemic fitness, and they highlight AGO2 as a potential biomarker and therapeutic target in myeloid leukemia.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Lazarenkov, A., Valcarcel, G., Martinez, A., Berenguer, C., Lopez-Rubio, A. V., Obiols, M., Fontanet, C., Rodriguez-Sevilla, J. J., Stik, G., Jeremias, I., Menendez, P., Sardina, J. L.. 2026-04-25. TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia. https://doi.org/10.64898/2026.04.23.719229
Cite the original work for its findings. Save a collection to share your selection of sources.